BR112023023035A2 - Composições de coronavírus e influenza e métodos para usá-las - Google Patents

Composições de coronavírus e influenza e métodos para usá-las

Info

Publication number
BR112023023035A2
BR112023023035A2 BR112023023035A BR112023023035A BR112023023035A2 BR 112023023035 A2 BR112023023035 A2 BR 112023023035A2 BR 112023023035 A BR112023023035 A BR 112023023035A BR 112023023035 A BR112023023035 A BR 112023023035A BR 112023023035 A2 BR112023023035 A2 BR 112023023035A2
Authority
BR
Brazil
Prior art keywords
coronavirus
methods
compositions
influenza
detergent
Prior art date
Application number
BR112023023035A
Other languages
English (en)
Portuguese (pt)
Inventor
D Portnoff Alyse
Bin Zhou
Gale Smith
Jing-Hui Tian
Louis Fries
J Massare Michael
Mimi Guebre-Xabier
Nita Patel
Vivek Shinde
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of BR112023023035A2 publication Critical patent/BR112023023035A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112023023035A 2021-05-05 2022-05-03 Composições de coronavírus e influenza e métodos para usá-las BR112023023035A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163184727P 2021-05-05 2021-05-05
US202163193356P 2021-05-26 2021-05-26
US202163255685P 2021-10-14 2021-10-14
US202263332537P 2022-04-19 2022-04-19
PCT/US2022/027465 WO2022235663A1 (en) 2021-05-05 2022-05-03 Coronavirus and influenza compositions and methods for using them

Publications (1)

Publication Number Publication Date
BR112023023035A2 true BR112023023035A2 (pt) 2024-01-23

Family

ID=83901839

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023035A BR112023023035A2 (pt) 2021-05-05 2022-05-03 Composições de coronavírus e influenza e métodos para usá-las

Country Status (11)

Country Link
US (1) US20220354944A1 (enExample)
EP (1) EP4333885A4 (enExample)
JP (1) JP2024516309A (enExample)
KR (1) KR20240024064A (enExample)
AU (1) AU2022270082A1 (enExample)
BR (1) BR112023023035A2 (enExample)
CA (1) CA3217591A1 (enExample)
IL (1) IL308180A (enExample)
MX (1) MX2023013081A (enExample)
TW (1) TW202308685A (enExample)
WO (1) WO2022235663A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
AU2021214064A1 (en) 2020-01-27 2022-08-18 Novavax, Inc. Coronavirus vaccine formulations
WO2024174012A1 (pt) * 2023-02-24 2024-08-29 Instituto Butantan Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal
AU2024253607A1 (en) * 2023-04-03 2025-10-16 Novavax, Inc. Coronavirus and influenza compositions and methods for using them
US20250085282A1 (en) * 2023-09-11 2025-03-13 Novavax, Inc. Method for detecting anti-sars-cov-2 spike (s) immunoglobulins
US20250144200A1 (en) * 2023-11-06 2025-05-08 Novavax, Inc. Intranasal immunogenic compositions
EP4670733A1 (en) * 2024-06-27 2025-12-31 Sanofi METHODS FOR PREPARING VIRAL PROTEINS AND THEIR USES

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
CA2805741C (en) 2010-07-23 2019-08-13 Karin Bengtsson Loevgren Composition including an iscom matrix and ectodomains
WO2012104820A1 (en) * 2011-02-04 2012-08-09 Pfizer Inc. Compositions for canine respiratory disease complex
EP3046579A1 (en) * 2013-09-19 2016-07-27 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
CN114617959A (zh) 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
WO2018081318A1 (en) 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
CN110418593B (zh) 2017-10-20 2022-04-19 科亚列士信荣株式会社 半成品卷制造装置
CN120227451A (zh) * 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
AU2021214064A1 (en) * 2020-01-27 2022-08-18 Novavax, Inc. Coronavirus vaccine formulations
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
EP4135762A4 (en) * 2020-04-14 2024-05-15 The Regents of the University of California Large sequence pan-coronavirus vaccine compositions
GB2596820A (en) * 2020-07-07 2022-01-12 Spicona Inc Combination vaccine
CN112546211A (zh) 2020-10-23 2021-03-26 嘉晨西海(杭州)生物技术有限公司 基于mRNA的针对冠状病毒和流感病毒的联合疫苗及其制备方法
CN112480217B (zh) * 2020-11-30 2022-04-08 广州阿格纳生物医药制造有限公司 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物
CN113185613B (zh) * 2021-04-13 2022-09-13 武汉大学 新型冠状病毒s蛋白及其亚单位疫苗

Also Published As

Publication number Publication date
MX2023013081A (es) 2024-01-15
IL308180A (en) 2024-01-01
US20220354944A1 (en) 2022-11-10
AU2022270082A1 (en) 2023-11-16
EP4333885A1 (en) 2024-03-13
EP4333885A4 (en) 2025-03-26
JP2024516309A (ja) 2024-04-12
CA3217591A1 (en) 2022-11-10
KR20240024064A (ko) 2024-02-23
TW202308685A (zh) 2023-03-01
WO2022235663A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
MX2023013081A (es) Composiciones de coronavirus e influenza y métodos para utilizarlas.
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
BR112021019724A2 (pt) Composições multifásicas enxaguáveis
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
BR112021019731A2 (pt) Composições para tratamento bucal para liberação de agente ativo
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
PE20140646A1 (es) Vacuna de virus de dengue inactivado
UA114086C2 (xx) Імуногенна композиція глікопротеїну g вірусу hendra і/або nipah
BR112014029774A2 (pt) uso de n-metil-n-acilglucaminas como agentes espessantes em soluções de tensoativos
MX347210B (es) Vacunas combinadas para prevención de infecciones por virus porcino.
BR112015001313A2 (pt) composições de vacina
MX2019004319A (es) Acorde de floracion de alto rendimiento, alto impacto.
BR112022025733A2 (pt) Vetores hvt recombinantes expressando hemaglutinina de influenza e composições imunogênicas, e produção e usos dos mesmos
MX363464B (es) Vacunas contra influenza h5.
BR112014014127A2 (pt) composições de higiene bucal
BR112015014243A2 (pt) composição de vacina para uso em populações imunocomprometidas
MX2019007973A (es) Composiciones universales de vacuna de la influenza.
AR089742A1 (es) Composicion para el tratamiento del cabello
BR112015017966A2 (pt) composições imunogênicas compreendendo vírus silificado e métodos de uso
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
BR112021019120A2 (pt) Células t específicas para antígenos de múltiplos vírus respiratórios e métodos de produção e uso das mesmas terapeuticamente
BR112014011345A2 (pt) partículas tipo vírus da influenza (vlps) compreendendo nicotiana tabacum produzida por hemaglutinina
MX2017009306A (es) Vacuna contra la fiebre aftosa.
BR112012022939A2 (pt) composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza
MX2025011740A (es) Composiciones de coronavirus e influenza y metodos para su uso